PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34247190-6 2021 Targeting MEK1 by RNAi or clinically applicable MEK1 inhibitors AZD6244 and GSK1120212 reduces MACC1 tyrosine phosphorylation and restricts MACC1-induced metastasis formation in mice. AZD 6244 64-71 mitogen-activated protein kinase kinase 1 Mus musculus 10-14 34247190-6 2021 Targeting MEK1 by RNAi or clinically applicable MEK1 inhibitors AZD6244 and GSK1120212 reduces MACC1 tyrosine phosphorylation and restricts MACC1-induced metastasis formation in mice. AZD 6244 64-71 mitogen-activated protein kinase kinase 1 Mus musculus 48-52 35287697-12 2022 The Homer1 protein and selumetinib, a non-ATP competitive MEK1/2 inhibitor, improved the outcome in ICH in Homer1flox/flox/Nestin-Cre+/- mice. AZD 6244 23-34 mitogen-activated protein kinase kinase 1 Mus musculus 58-64 31786775-3 2020 In the present study, the effect of AZD6244 (an ATP non-competitive MEK1/2 inhibitor) on acrolein-induced neuroinflammation was investigated using BV-2 cells and primary cultured microglia. AZD 6244 36-43 mitogen-activated protein kinase kinase 1 Mus musculus 68-74 32358092-5 2020 Mice were treated with interferon gamma (IFNgamma) intraperitoneally for 3 days or with the mitogen-activated protein kinase kinase (MEK1/2) inhibitor selumetinib by oral gavage for 24 hours. AZD 6244 151-162 mitogen-activated protein kinase kinase 1 Mus musculus 133-139 32102484-6 2020 Additional targeting of the RAS/RAF/MEK/MAPK pathway with the allosteric MEK1/2 inhibitor AZD6244 showed synergistic effects on the viability of MPNST cell lines in vitro in comparison to the dual AKT/mTOR inhibition. AZD 6244 90-97 mitogen-activated protein kinase kinase 1 Mus musculus 73-79 25541062-3 2015 Using KRAS-mutant NSCLC cells and a mouse model, we evaluated the efficacy of adding the MEK1/2 inhibitor AZD6244 as an addition for cisplatin-based chemotherapy. AZD 6244 106-113 mitogen-activated protein kinase kinase 1 Mus musculus 89-95 22144664-0 2012 MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model. AZD 6244 17-28 mitogen-activated protein kinase kinase 1 Mus musculus 0-6 24448821-7 2014 We found that the acquired MEK1-C121S mutation in BRAF-V600E mutant melanoma conferred resistance to both vemurafenib and selumetinib but not E6201. AZD 6244 122-133 mitogen-activated protein kinase kinase 1 Mus musculus 27-31 24132923-0 2013 Development, characterization, and reversal of acquired resistance to the MEK1 inhibitor selumetinib (AZD6244) in an in vivo model of childhood astrocytoma. AZD 6244 89-100 mitogen-activated protein kinase kinase 1 Mus musculus 74-78 24132923-0 2013 Development, characterization, and reversal of acquired resistance to the MEK1 inhibitor selumetinib (AZD6244) in an in vivo model of childhood astrocytoma. AZD 6244 102-109 mitogen-activated protein kinase kinase 1 Mus musculus 74-78 25326806-2 2015 AZD6244 is a potent, selective, and orally available MEK1/2 inhibitor. AZD 6244 0-7 mitogen-activated protein kinase kinase 1 Mus musculus 53-59 23508762-4 2013 Therefore, in the current study, we investigated the effect of inhibiting the growth factor receptor pathways with a MEK-1/2 inhibitor selumetinib (AZD6244, ARRY-142866). AZD 6244 135-146 mitogen-activated protein kinase kinase 1 Mus musculus 117-124 22144664-0 2012 MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model. AZD 6244 30-37 mitogen-activated protein kinase kinase 1 Mus musculus 0-6 20407895-1 2011 PURPOSE: AZD6244 (ARRY-142886) (AstraZeneca, Macclesfield, UK) is a novel small molecule MEK1/2 inhibitor that is currently being tested in Phase II trials. AZD 6244 9-16 mitogen-activated protein kinase kinase 1 Mus musculus 89-95 17237274-3 2007 In the present study, we determined the efficacy of a specific MEK1/2 inhibitor AZD6244 (ARRAY-142886) in treatment of HCC. AZD 6244 80-87 mitogen-activated protein kinase kinase 1 Mus musculus 63-69